STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG), a biotechnology company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that the primary endpoint (safety and tolerability) was met in the Phase 1b part of a trial combining TG4001 and avelumab, a human anti-programmed death ligand (PD-L1) antibody, as a treatment for HPV-16+1 recurrent or metastatic malignancies, such as oropharyngeal squamous cell carcinoma of the head and neck (SCCHN).
In the Phase 1b part of the trial, 9 patients received escalating doses of TG4001 combined with a fixed dose of avelumab. No dose-limiting toxicity was observed, confirming a satisfactory tolerability profile for the combined regimen, allowing the trial to progress to the Phase 2 part.
The Phase 2 part of the trial will enroll 40 patients with HPV16+ recurrent or metastatic SCCHN. Patients will receive the highest TG4001 dose tested in the Phase 1b part of the trial, in combination with avelumab at 10 mg/kg, until disease progression. The first patients have already been enrolled.
The first data from this trial on the activity of the combination are expected during the second half of 2019.
About the trial
This multi-center, open-label trial
will assess the safety and tolerability, as well as the anti-tumor
activity of this immunotherapy combination regimen (TG4001 + avelumab)
in up to 50 patients (NCT03260023). Prof. Christophe Le Tourneau, M.D.,
PhD, Head of the Department of Drug Development and Innovation (D3i)
at the Curie Institute, and a world expert in head and neck cancers, is
the Principal Investigator of the study. The trial is conducted in
collaboration with Merck KGaA, Darmstadt, Germany, a leading science and
technology company which in the US and Canada operates its
biopharmaceutical business as EMD Serono, and Pfizer Inc (NYSE: PFE).
More information on the trial is available on clinicaltrials.gov.
-End-
Notes to editors
About TG4001
TG4001 is an investigational therapeutic
vaccine based on a non-propagative, highly attenuated vaccinia vector
(MVA), which is engineered to express HPV-16 antigens (E6 & E7) and an
adjuvant (IL-2). TG4001 is designed to have a two-pronged antiviral
approach: to alert the immune system specifically to HPV-16-infected
cells that have started to undergo precancerous transformation (cells
presenting the HPV-16 E6 and E7 antigens) and to further stimulate the
infection-clearing activity of the immune system through interleukin 2
(IL-2). TG4001 has been administered to more than 300 individuals,
demonstrating good safety, significant HPV clearance rate and promising
efficacy results. Its mechanism of action and good safety profile make
TG4001 an excellent candidate for combinations with other therapies in
HPV-mediated solid tumors.
About Avelumab
Avelumab is a human anti-programmed
death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical
models to engage both the adaptive and innate immune functions. By
blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been
shown to release the suppression of the T cell-mediated antitumor immune
response in preclinical models.1-3 Avelumab has also been
shown to induce NK cell-mediated direct tumor cell lysis via
antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro3-5.
In November 2014, Merck KGaA, Darmstadt, Germany, and Pfizer announced a
strategic alliance to co-develop and co-commercialize avelumab.
Approved Indications
The US Food and Drug
Administration (FDA) granted accelerated approval for avelumab
(BAVENCIO®) for the treatment of (i) adults and pediatric patients 12
years and older with metastatic Merkel cell carcinoma (mMCC) and (ii)
patients with locally advanced or metastatic urothelial carcinoma (mUC)
who have disease progression during or following platinum-containing
chemotherapy, or have disease progression within 12 months of
neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
These indications are approved under accelerated approval based on tumor
response rate and duration of response. Continued approval for these
indications may be contingent upon verification and description of
clinical benefit in confirmatory trials.
Avelumab is currently approved for patients with MCC in more than 45 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.
Important Safety Information from the US FDA-Approved Label
The
warnings and precautions for avelumab (BAVENCIO®) include
immune-mediated adverse reactions (such as pneumonitis, hepatitis,
colitis, endocrinopathies, nephritis and renal dysfunction and other
adverse reactions), infusion-related reactions and embryo-fetal toxicity.
Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO® for mMCC and patients with locally advanced or metastatic UC include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash.
For full prescribing information and medication guide for BAVENCIO®, please see www.BAVENCIO.com.
About HPV-Positive Head and Neck Cancer
Squamous cell
carcinoma of the head and neck (SCCHN) is a heterogeneous group of
cancers that can affect the oral cavity, pharynx, and larynx.
The incidence of HPV-related SCCHN has significantly increased in recent years. HPV-16 infection is associated with more than 85% of oropharynx squamous cell carcinomas in the US (Kreimer et al., 2005), i.e. more than 25,000 patients (Source: meta-analysis, IARC - De Martel et al., 2017, International Journal of Cancer).
Current treatments include surgical resection with radiotherapy, chemoradiotherapy or immune checkpoint inhibitors. However, better options are needed for advanced and metastatic HPV+ SCCHN. It is thought that immunotherapy combined with immune checkpoint inhibitors could provide a promising potential treatment option that would address this strong medical need.
About Transgene
Transgene (Euronext: TNG) is a
publicly traded French biotechnology company focused on designing and
developing targeted immunotherapies for the treatment of cancer and
infectious diseases. Transgene’s programs utilize viral vector
technology with the goal of indirectly or directly killing infected or
cancerous cells. The Company’s lead clinical-stage programs are: TG4010,
a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an
oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine
against HPV-positive head and neck cancers. The Company has several
other programs in clinical development, including TG1050 (a therapeutic
vaccine for the treatment of chronic hepatitis B) and TG6002 (an
oncolytic virus for the treatment of solid tumors).
With its proprietary Invir.IO™, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.
myvac™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio.
Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
Disclaimer
This press release contains
forward-looking statements, which are subject to numerous risks and
uncertainties, which could cause actual results to differ materially
from those anticipated. There can be no guarantee that (i) the results
of preclinical work and prior clinical trials will be predictive of the
results of the clinical trials currently underway, (ii) regulatory
authorities will agree with the Company’s further development plans for
its therapies, or (iii) the Company will find development and
commercialization partners for its therapies in a timely manner and on
satisfactory terms and conditions, if at all. The occurrence of any of
these risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results and development.
For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Document de Référence, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
References
1Dolan DE, Gupta S. PD-1
pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer
Control 2014;21(3):231-7.
2Dahan R, Sega E,
Engelhardt J et al. FcγRs modulate the anti-tumor activity of antibodies
targeting the PD-1/PD-L1 axis. Cancer Cell 2015;28(3):285-95.
3Boyerinas
B, Jochems C, Fantini M et al. Antibody-dependent cellular cytotoxicity
activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human
tumor cells. Cancer Immunol Res 2015;3(10):1148-57.
4Kohrt
HE, Houot R, Marabelle A et al. Combination strategies to enhance
antitumor ADCC. Immunotherapy 2012;4(5):511-27.
5Hamilton
G, Rath B. Avelumab: combining immune checkpoint inhibition and
antibody-dependent cytotoxicity. Expert Opin Biol Ther 2017;17(4):515-7
----------
1Human papillomavirus type 16: HPV-16 is known to be one of the causing agents of a variety of cancers (see notes to the editors)
